Last $38.31 USD
Change Today -0.11 / -0.29%
Volume 227.0K
As of 8:10 PM 11/26/14 All times are local (Market data is delayed by at least 15 minutes).

kythera biopharmaceuticals i (KYTH) Snapshot

Open
$38.32
Previous Close
$38.42
Day High
$38.49
Day Low
$38.00
52 Week High
02/26/14 - $56.36
52 Week Low
05/9/14 - $29.50
Market Cap
868.7M
Average Volume 10 Days
187.7K
EPS TTM
$-4.12
Shares Outstanding
22.7M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for KYTHERA BIOPHARMACEUTICALS I (KYTH)

Related News

No related news articles were found.

kythera biopharmaceuticals i (KYTH) Related Businessweek News

No Related Businessweek News Found

kythera biopharmaceuticals i (KYTH) Details

KYTHERA Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of prescription products for the aesthetic medicine market. It is developing ATX-101, is an injectable drug in late stage clinical development for the reduction of submental fat, which commonly presents as an undesirable double chin. The company also has various additional research programs around therapeutic intervention for hair loss; and maintains active research interest in hair and fat biology, pigmentation modulation, and facial contouring. KYTHERA Biopharmaceuticals, Inc. has a collaboration arrangement with Bayer Consumer Care AG and a related collaboration agreement with Bayer Consumer Care AG’s affiliate, Intendis GmbH to develop and commercialize ATX-101 outside the United States and Canada. The company was formerly known as AESTHERx, Inc. and changed its name to KYTHERA Biopharmaceuticals, Inc. in July 2006. KYTHERA Biopharmaceuticals, Inc. was founded in 2004 and is headquartered in Calabasas, California.

89 Employees
Last Reported Date: 11/10/14
Founded in 2004

kythera biopharmaceuticals i (KYTH) Top Compensated Officers

Co-Founder, Chief Executive Officer, Presiden...
Total Annual Compensation: $448.7K
Chief Financial Officer and Principal Account...
Total Annual Compensation: $312.7K
Chief Medical Officer
Total Annual Compensation: $348.8K
Compensation as of Fiscal Year 2013.

kythera biopharmaceuticals i (KYTH) Key Developments

Kythera Biopharmaceuticals, Inc. Reports Earnings Results Third Quarter and Nine Months Ended September 30, 2014

Kythera Biopharmaceuticals, Inc. reported earnings results third quarter and nine months ended September 30, 2014. For the quarter, the company reported loss from operations of $21.311 million against $11.004 million a year ago. Net loss was $22.471 million or $0.99 per basic and diluted share against $11.509 million or $0.62 per basic and diluted share a year ago. For the nine months, the company reported loss from operations of $108.495 million against $36.502 million a year ago. Net loss was $111.398 million or $4.97 per basic and diluted share against $37.893 million or $2.05 per basic and diluted share a year ago.

Kythera Biopharmaceuticals, Inc. to Report Q3, 2014 Results on Nov 10, 2014

Kythera Biopharmaceuticals, Inc. announced that they will report Q3, 2014 results at 4:30 PM, US Eastern Standard Time on Nov 10, 2014

Kythera Biopharmaceuticals, Inc., Q3 2014 Earnings Call, Nov 10, 2014

Kythera Biopharmaceuticals, Inc., Q3 2014 Earnings Call, Nov 10, 2014

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
KYTH:US $38.31 USD -0.11

KYTH Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for KYTH.
View Industry Companies
 

Industry Analysis

KYTH

Industry Average

Valuation KYTH Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 10.9x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact KYTHERA BIOPHARMACEUTICALS I, please visit www.kytherabiopharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.